The Wnt/beta-Catenin Pathway in Cancer

The Destruction Complex

In the absence of a Wnt signal, cytoplasmic beta-catenin is captured by a destruction complex containing the scaffold proteins APC and AXIN and the kinases CK1 and GSK-3-beta. These kinases phosphorylate beta-catenin, marking it for ubiquitination and proteasomal degradation.

This keeps nuclear beta-catenin low, and Wnt target genes stay off, held down by TCF/LEF transcription factors bound to co-repressors.

How a Wnt Signal Switches It On

When a Wnt ligand binds the Frizzled receptor and its co-receptor LRP5/6, the destruction complex is recruited to the membrane and inactivated. Beta-catenin then accumulates, enters the nucleus, and converts TCF/LEF into transcriptional activators.

Target genes include MYC, cyclin D1 and AXIN2, linking the pathway directly to proliferation and to its own feedback control.

Constitutive Activation in Cancer

Most colorectal cancers carry biallelic loss-of-function mutations in APC, which cripple the destruction complex so beta-catenin accumulates regardless of Wnt input. Familial adenomatous polyposis is the inherited form of APC loss.

A minority of tumours instead have activating mutations in CTNNB1 (the beta-catenin gene) that remove its phosphorylation sites, or loss of AXIN1 or the ubiquitin ligase component RNF43. These are recurrent in hepatocellular carcinoma, endometrial cancer and others.

Why It Is Hard to Drug

The main oncogenic lesion, APC loss, acts downstream of the receptor, so drugs that block Wnt ligands or Frizzled (porcupine inhibitors, anti-Frizzled antibodies) only help the smaller group of tumours driven by upstream signalling, such as RNF43-mutant cancers.

Directly blocking the beta-catenin-TCF interaction has been difficult because it is a large, flat protein-protein interface. Tankyrase inhibitors that stabilise AXIN are in trials but have a narrow therapeutic window.

Interpretation Notes

Nuclear beta-catenin staining by immunohistochemistry is used diagnostically in specific tumours, but it is a readout of pathway activity, not a standalone treatment-selection test.

An APC or CTNNB1 finding indicates pathway activation and, for APC, may raise a question about inherited polyposis that is addressed through clinical genetics.

Key Takeaways

• ·The destruction complex (APC, AXIN, CK1, GSK-3-beta) normally degrades beta-catenin.
• ·A Wnt signal, or loss of APC, lets beta-catenin accumulate and drive MYC and cyclin D1.
• ·APC loss defines most colorectal cancer; CTNNB1, AXIN1 and RNF43 changes occur elsewhere.
• ·Upstream Wnt drugs only help tumours driven above the destruction complex.